Cognition Therapeutics (CGTX) Retained Earnings (2020 - 2026)
Cognition Therapeutics (CGTX) reported Retained Earnings of -$203.2 million for Q1 2026, down 10.66% year-over-year from -$227.5 million in Q1 2025, and down 2.3% on a QoQ basis from -$198.6 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Retained Earnings data on file, last reported at -$203.2 million in Q1 2026.
- Quarterly Retained Earnings fell 10.66% year-over-year to -$203.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$203.2 million (down 10.66% YoY) and the FY2025 annual result came in at -$198.6 million, down 13.41% from the prior year.
- Retained Earnings fell to -$203.2 million in Q1 2026 per CGTX's latest filing, from -$198.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$195000.0 in Q1 2023 and bottomed at -$203.2 million in Q1 2026.
- The 5-year median for Retained Earnings is -$150.3 million (2024), against an average of -$122.6 million.
- The widest annual swing landed in 2023, when Retained Earnings jumped 99.83%; it then tumbled 89725.64% in 2024.
- Tracing CGTX's Retained Earnings over 5 years: stood at -$115.4 million in 2022, then jumped by 99.83% to -$195000.0 in 2023, then plunged by 89725.64% to -$175.2 million in 2024, then fell by 13.41% to -$198.6 million in 2025, then declined by 2.3% to -$203.2 million in 2026.
- Per Business Quant, the three latest CGTX Retained Earnings figures stand at -$203.2 million (Q1 2026), -$198.6 million (Q4 2025), and -$195.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 36.42 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 130.89 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -203.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -203.22 Mn |
| Dec 31, 2025 | -198.65 Mn |
| Sep 30, 2025 | -195.30 Mn |
| Jun 30, 2025 | -190.37 Mn |
| Mar 31, 2025 | -183.64 Mn |
| Dec 31, 2024 | -175.16 Mn |
| Sep 30, 2024 | -167.32 Mn |
| Jun 30, 2024 | -157.38 Mn |
| Mar 31, 2024 | -150.34 Mn |
| Dec 31, 2023 | -195,000.00 |
| Sep 30, 2023 | -133.05 Mn |
| Jun 30, 2023 | -196,000.00 |
| Mar 31, 2023 | -195,000.00 |
| Dec 31, 2022 | -115.40 Mn |
| Sep 30, 2022 | -110.22 Mn |
| Jun 30, 2022 | -103.59 Mn |
| Mar 31, 2022 | -197,000.00 |
| Dec 31, 2021 | -94.00 Mn |
| Sep 30, 2021 | -86.67 Mn |
| Dec 31, 2020 | -187,000.00 |